You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 9,265,762

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,265,762

Title:	Stable pharmaceutical compositions comprising a pyrimidine-sulfamide
Abstract:	The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof. ##STR00001##
Inventor(s):	Adesuyi; Charles Tokunbo (Swindon, GB), Lithgow; Bruce Hamilton (Bath, GB), Lambert; Olivier (Spechbach-le-Haut, FR), Holman; Lovelace (Arlesheim, CH)
Assignee:	ACTELION PHARMACEUTICALS LTD. (Allschwil, CH)
Application Number:	13/736,699
Patent Claims:	1. A pharmaceutical composition comprising: a) the compound of the formula I as drawn below ##STR00004## or a pharmaceutically acceptable salt, solvate, hydrate or morphological form thereof, b) a filler, consisting of lactose monohydrate with microcrystalline cellulose, c) a disintegrant, consisting of sodium starch glycolate or a combination of sodium starch glycolate and polyvinylpyrrolidone, d) a surfactant, consisting of a polysorbate, in a total amount of 0.1 to 3% in weight based on the total weight of the pharmaceutical composition, and e) a lubricant, consisting of magnesium stearate. 2. The pharmaceutical composition according to claim 1, wherein the polysorbate is polysorbate 80. 3. The pharmaceutical composition according to claim 1, wherein the disintegrant is consisting of a combination of sodium starch glycolate and polyvinylpyrrolidone. 4. The pharmaceutical composition according to claim 3, wherein the combination of sodium starch glycolate and polyvinylpyrrolidone is present in a total amount of 2 to 10% in weight based on the total weight of the pharmaceutical composition. 5. The pharmaceutical composition according to claim 1, wherein the magnesium stearate is present in a total amount of between 0.1 to 1% in weight based on the total weight of the pharmaceutical composition. 6. The pharmaceutical composition according to claim 1, which is in the form of a capsule. 7. The pharmaceutical composition according to claim 1, which is in the form of a tablet. 8. A method of treating pulmonary arterial hypertension comprising the administration to a patient in need thereof a pharmaceutical composition according to claim 1. 9. The pharmaceutical composition according to claim 1, comprising: a) the compound of the formula I as drawn below ##STR00005## or a pharmaceutically acceptable salt, solvate, hydrate or morphological form thereof, in a total amount of up to 50% in weight based on the total weight of the pharmaceutical composition, b) a filler, consisting of lactose monohydrate with microcrystalline cellulose, in a total amount of 10 to 95% in weight based on the total weight of the pharmaceutical composition, c) a disintegrant, consisting of sodium starch glycolate or a combination of sodium starch glycolate and polyvinylpyrrolidone, in a total amount of 1 to 20% in weight based on the total weight of the pharmaceutical composition, d) a surfactant, consisting of a polysorbate, in a total amount of 0.1 to 3% in weight based on the total weight of the pharmaceutical composition, and e) a lubricant, consisting of magnesium stearate, in a total amount of 0.05 to 10% in weight based on the total weight of the pharmaceutical composition. 10. The pharmaceutical composition according to claim 9, wherein the polysorbate is polysorbate 80. 11. The pharmaceutical composition according to claim 9, wherein the disintegrant is consisting of a combination of sodium starch glycolate and polyvinylpyrrolidone. 12. The pharmaceutical composition according to claim 11, wherein the combination of sodium starch glycolate and polyvinylpyrrolidone is present in a total amount of 2 to 10% in weight based on the total weight of the pharmaceutical composition. 13. The pharmaceutical composition according to claim 9, wherein the magnesium stearate is present in a total amount of between 0.1 to 1% in weight based on the total weight of the pharmaceutical composition. 14. The pharmaceutical composition according to claim 9, which is in the form of a capsule. 15. The pharmaceutical composition according to claim 9, which is in the form of a tablet. 16. A method of treating pulmonary arterial hypertension comprising the administration to a patient in need thereof a pharmaceutical composition according to claim 9.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.